UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Acquires New Shares in Pulse Biosciences, Inc. (NASDAQ:PLSE)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new position in Pulse Biosciences, Inc. (NASDAQ:PLSE - Free Report) in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 33,535 shares of the company's stock, valued at approximately $588,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned about 0.05% of Pulse Biosciences as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of PLSE. Charles Schwab Investment Management Inc. lifted its position in shares of Pulse Biosciences by 193.0% during the third quarter. Charles Schwab Investment Management Inc. now owns 148,114 shares of the company's stock valued at $2,598,000 after purchasing an additional 97,565 shares in the last quarter. Creative Planning increased its stake in Pulse Biosciences by 113.9% in the 3rd quarter. Creative Planning now owns 21,910 shares of the company's stock valued at $384,000 after buying an additional 11,667 shares during the last quarter. Quest Partners LLC bought a new position in shares of Pulse Biosciences during the 2nd quarter worth approximately $91,000. Bank of New York Mellon Corp boosted its stake in shares of Pulse Biosciences by 23.4% in the 2nd quarter. Bank of New York Mellon Corp now owns 50,914 shares of the company's stock worth $570,000 after buying an additional 9,639 shares during the last quarter. Finally, Rhumbline Advisers grew its holdings in shares of Pulse Biosciences by 6.7% in the second quarter. Rhumbline Advisers now owns 25,729 shares of the company's stock valued at $288,000 after acquiring an additional 1,608 shares in the last quarter. Institutional investors own 76.95% of the company's stock.

Insider Activity at Pulse Biosciences

In other news, Director Robert W. Duggan acquired 55,256 shares of the firm's stock in a transaction that occurred on Friday, December 13th. The stock was bought at an average price of $17.18 per share, with a total value of $949,298.08. Following the acquisition, the director now owns 42,328,717 shares in the company, valued at $727,207,358.06. The trade was a 0.13 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Burke Thomas Barrett sold 50,000 shares of the company's stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $17.42, for a total transaction of $871,000.00. Following the sale, the chief executive officer now directly owns 63,172 shares in the company, valued at approximately $1,100,456.24. This trade represents a 44.18 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 71.50% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Separately, StockNews.com upgraded Pulse Biosciences to a "sell" rating in a report on Thursday, December 12th.

Pulse Biosciences Trading Up 1.1 %

Shares of NASDAQ PLSE traded up $0.19 during mid-day trading on Friday, reaching $17.98. 166,773 shares of the company's stock were exchanged, compared to its average volume of 200,640. The firm has a 50-day moving average price of $17.91 and a two-hundred day moving average price of $16.62. Pulse Biosciences, Inc. has a 52 week low of $6.59 and a 52 week high of $22.69.

Pulse Biosciences (NASDAQ:PLSE - Get Free Report) last announced its quarterly earnings data on Wednesday, October 30th. The company reported ($0.21) EPS for the quarter. During the same period last year, the company earned ($0.19) EPS.

Pulse Biosciences Profile

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.